Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

View:
Post by Mole101 on Jul 02, 2021 7:57am

AGM

In particular, the following are the voting results for the 103,137,426 common shares that were voted in person or by proxy at the Meeting.

1.   The following directors were elected, with each nominee receiving a minimum majority of 75% of the votes cast:

   DIRECTOR FOR WITHHELD
Eugene Williams 55,876,666 18,219,274
Neil Cashman, M.D. 73,388,087 707,853
Richard J. Gregory, PH.D. 67,464,866 6,631,074
Patrick D. Kirwin 67,364,166 6,731,744
Neil K. Warma 69,534,991 4,560,949
William Wyman 56,967,143 17,128,797

2.   PricewaterhouseCoopers LLP, Chartered Professional Accountants, were appointed auditor of the Company and the Board authorized to fix the auditor’s remuneration. Shares voted in person and by proxies received represented 103,279,732 votes FOR and 1,720,193 votes WITHHELD.

3.   The ordinary resolution to authorize the Corporation to grant options pursuant to the Corporation’s 20% rolling Stock Option Plan until June 30, 2024 was passed by a majority vote of the disinterested shareholders of the Corporation. Shares voted in person and by proxies received represented 27,706,467 votes FOR and 17,043,875 votes AGAINST. The above vote tally on this resolution is of votes of the disinterested shareholders only because votes representing 29,345,598 Common Shares of Insiders were excluded from the vote tally.

https://ceo.ca/@nasdaq/promis-neurosciences-announces-results-of-annual-meeting-1d919

Comment by Gbathat on Jul 02, 2021 10:29am
This is good news, in that the majority of existing shareholders are good with the current leadership and indirectly the business plan. I presume most of those voting have more DD and skin in the game than me. there are a significant votes against Williams and Wyman, though relative to the others.  Makes sense as they are the ones at the negotiating table and some investors have lost ...more  
Comment by Gbathat on Jul 02, 2021 10:32am
Now let's make a deal PMN!  We aren't getting any younger, and AD is a 'pandemic' that isn't going away. Get'r done. This mission is too important to delay.
Comment by DavidKingCanada on Jul 02, 2021 10:38am
Overall great meeting! Let's make some deals happen! 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities